References
1. Konjeviс G.M., Vuletiс A.M., Mirjaсiс Martinoviс K.M., Jurisic V.B. The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine. 2019; 117: 30–40. DOI: https://www.doi.org/10.1016/j.cyto.2019.02.001
2. Khamatova A.A., Chebotareva T.A., Balmasova I.P. Tissue-resident natural killer cells: features of functioning in the uterus and decidual membrane. Immunologiya. 2021; 42 (5): 574–80. DOI: https://doi.org/10.33029/0206-4952-2021-42-5-574-580 (in Russian)
3. Barrow A.D., Edeling M.A., Trifonov V., Luo J., et al. Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor. Cell. 2018; 172 (3): 534–48. DOI: https://www.doi.org/10.1016/j.cell.2017.11.037
4. Montaldo E., Vacca P., Vitale C., Moretta F., et al. Human innate lymphoid cells. Immunol Lett. 2016; 179: 2–8. DOI: https://www.doi.org/10.1016/j.imlet.2016.01.007
5. Lanier L.L., Le A.M., Civin C.I., Loken M.R., et al. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986; 136 (12): 4480–6. DOI: https://www.doi.org/doi.org/10.4049/jimmunol.136.12.4480
6. Cooper M.A., Fehniger T.A., Caligiuri M.A. Review. The biology of human natural killer-cell subsets. Trends in Immunology. 2001; 22 (11): 633–40. DOI: https://www.doi.org/10.1016/s1471-4906(01)02060-9
7. Min-Oo G., Kamimura Y., Hendricks D.W., Nabekura T., et al. Natural killer cells: walking three paths down memory lane. Trends Immunol. 2013; 34 (6): 251–8. DOI: https://www.doi.org/10.1016/j.it.2013.02.005
8. Stojanovic A., Correia M.P., Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron. 2013; 6 (2): 135–46. DOI: https://www.doi.org/10.1007/s12307-012-0125-8
9. Zwirner N.W., Domaica C.I. Cytokine regulation of natural killer cell effector functions. Biofactors. 2010; 36 (4): 274–88. DOI: https://www.doi.org/10.1002/biof.107
10. Khalil M., Wang D., Hashemi E., Terhune S.S., et al. Implications of a Third signal in NK cells. Cells. 2021; 10 (8): 1955. DOI: https://www.doi.org/10.3390/cells10081955
11. Okamura H., Tsutsi H., Komatsu T., Yutsudo M. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995; 37 8 (6552): 88–91. DOI: https://www.doi.org/10.1038/378088a0
12. Lee J.K., Kim S.H., Lewis E.C., Azam T., et al. Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci U S A. 2004; 101 (23): 8815–20. DOI: https://www.doi.org/10.1073/pnas.0402800101
13. Terme M., Ullrich E., Aymeric L., Meinhardt K., et al. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 2012; 72 (11): 2757–67. DOI: https://www.doi.org/10.1158/0008-5472.CAN-11-3379
14. Zwirner N.W., Ziblat A. Regulation of NK cell activation and effector functions by the IL-12 family of cytokines: The Case of IL-27. Front Immunol. 2017; 8: 25. DOI: https://www.doi.org/10.3389/fimmu.2017.00025
15. Wang R., Jaw J.J., Stutzman N.C., Zou Z., et al. Natural killer cell-produced IFN-γ and TNF-α induce target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol. 2012; 91 (2): 299–309. DOI: https://www.doi.org/10.1189/jlb.0611308
16. Choi Y.H., Lim E.J., Kim S.W., Moon Y.W. et al. IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells. J Immunother Cancer. 2019; 7 (1): 168. DOI: https://www.doi.org/10.1186/s40425-019-0652-7
17. Pot C., Apetoh L., Awasthi A., Kuchroo V.K. Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. Semin Immunol. 2011; 23 (6): 438–45. DOI: https://www.doi.org/10.1016/j.smim.2011.08.003
18. Mirlekar B., Pylayeva-Gupta Y. IL-12 Family cytokines in cancer and immunotherapy. Cancers (Basel). 2021; 13 (2): 167. DOI: https://www.doi.org/10.3390/cancers13020167
19. Collison L.W., Delgoffe G.M., Guy C.S., Vignali K.M., et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol. 2012; 13 (3): 290–9. DOI: https://www.doi.org/10.1038/ni.2227
20. Collison L.W., Vignali D.A. Interleukin-35: odd one out or part of the family? Immunol Rev. 2008; 226: 248–62. DOI: https://www.doi.org/10.1111/j.1600-065X.2008.00704.x
21. Olson B.M., Sullivan J.A., Burlingham W.J. Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol. 2013; 4: 315. DOI: https://www.doi.org/10.3389/fimmu.2013.00315
22. Zhang N., Dai H., Dong X., Liu W., et al. Level of interleukin-35 in patients with idiopathic membranous nephropathy and its predictive value for remission time. Frontiers in Immunology. 2022; 926: 368–81. DOI: https://www.doi.org/10.3389/fimmu.2022.926368
23. Liu K., Huang A., Nie J., Tan J., et al. IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment. Front Immunol. 2021; 12: 683332. DOI: https://www.doi.org/10.3389/fimmu.2021.683332
24. Wu H., Li P., Shao N., Ma J., et al. Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia. Oncol Lett. 2012; 3 (5): 1119–23. DOI: https://www.doi.org/10.3892/ol.2012.614
25. Gu X., Tian T., Zhang B., Liu Y., et al. Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. Tumour Biol. 2015; 36 (4): 2651–6. DOI: https://www.doi.org/10.1007/s13277-014-2887-8
26. Malyshkina A.I., Voskresenskaya D.L., Voronin D.N., Antsiferova Y.A., et al. Immune mechanisms of regulating the growth of uterine leiomyoma. Akusherstvo i Ginekologiya. 2020; 2: 111–115. DOI://dx.doi.org/10.18565/aig.2020.2.111-115. (in Russian)
27. Fehniger T.A., Cooper M.A. Harnessing NK cell memory for cancer immunotherapy. Trends Immunol. 2016; 37 (12): 877–88. DOI: https://www.doi.org/10.1016/j.it.2016.09.005
28. Ames E., Murphy W.J. Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol Immunother. 2014; 63 (1): 21–8. DOI: https://www.doi.org/10.1007/s00262-013-1469-8
29. Romee R., Rosario M., Berrien-Elliott M.M., Wagner J.A., et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016; 8 (357): 357ra123. DOI: https://www.doi.org/10.1126/scitranslmed.aaf2341
30. Vacchelli E., Bloy N., Aranda F., Buquуe A., et al. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology. 2016; 5 (9): e1214790. DOI: https://www.doi.org/10.1080/2162402X.2016.1214790
31. Setrerrahmane S., Xu H. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. 2017; 16 (1): 153. DOI: https://www.doi.org/10.1186/s12943-017-0721-9. PMID: 28927416